Markets

Ocular Therapeutix, Inc. (OCUL), Veritone, Inc. (VERI)

Ocular Therapeutix, Inc. (OCUL), Veritone, Inc. (VERI)

(NASDAQ:OCUL) during the first quarter, according to its most recent disclosure with the SEC. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company's stock valued at $3,705,000 after buying an additional 284,200 shares in the last quarter. Ocular Therapeutix earned a daily sentiment score of 0.17 on Accern's scale. State Street Corp boosted its stake in shares of Ocular Therapeutix by 21.8% in the fourth quarter. Cantor Fitzgerald analyst E. Piros now anticipates that the biopharmaceutical company will post earnings of ($2.09) per share for the year, up from their prior estimate of ($2.63). Renaissance Technologies LLC acquired a new stake in shares of Ocular Therapeutix during the fourth quarter valued at $1,214,000. Vanguard Group Inc. now owns 902,262 shares of the biopharmaceutical company's stock worth $8,373,000 after buying an additional 174,688 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Ocular Therapeutix during the first quarter valued at about $110,000. Columbus Circle Investors increased its stake in Ocular Therapeutix by 131.4% in the first quarter.

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has gone stronger by 29.45%. Zooming out to the 200-day moving average, shares have been seen trading -22.00% away from that value. Ocular Therapeutix has a one year low of $4.04 and a one year high of $11.91. The company has a market cap of $1.98B and its 12 month revenue was nearly $3.24B.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.10. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.58. It has a return on equity (ROE) of -80.20%.

Many analysts have provided their estimated foresights on Ocular Therapeutix, Inc.

08/05/2015 - Nomura began new coverage on Ocular Therapeutix, Inc. giving the company a " rating. If you are reading this news story on another website, it was stolen and reposted in violation of worldwide trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/07/16/ocular-therapeutix-inc-nasdaqocul-position-held-by-nationwide-fund-advisors.html.

Here's how Katrina Kaif celebrated her birthday
Besides Salman and Katrina's epochal pairing, the film elicits euphoria as it promises to be an adrenaline-pumping actioner. Well, that's what Twitterati have been joking about ever since an editor goofed-up with the footage of IIFA Awards 2017.

A number of other research analysts also recently issued reports on OCUL.

Insider Trades for Ocular Therapeutix, Inc. show that the latest trade was made on 14 Dec 2016 where Sawhney (Amarpreet), the Chief Executive Officer completed a transaction type "Buy" in which 45300 shares were traded at a price of $7.85. Zacks Investment Research raised shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a report on Wednesday, March 22nd.

The collective rating of 2.4 for Ocular Therapeutix, Inc. Finally, ValuEngine lowered Ocular Therapeutix from a "hold" rating to a "sell" rating in a research note on Tuesday, July 11th. Wellington Management Group LLP now owns 1,312,703 shares of the biopharmaceutical company's stock worth $12,182,000 after buying an additional 341,767 shares during the last quarter. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.

While looking at the Stock's Performance, Ocular Therapeutix, Inc. now shows a Weekly Performance of -29.95%, where Monthly Performance is -38.89%, Quarterly performance is -21.34%, 6 Months performance is -14.02% and yearly performance percentage is 34.17%.